Emory University

The Florida State University Research Foundation, Inc

Zackery Will Dentmon

Dennis C Liotta

James P Snyder

Richard K Plemper

Edgars Jecs

Stephen Pelly

Qi Shi

Thomas Kaiser

Christopher Dalloul

John DiRaddo

Julien Sourimant

Robert Wilson

The present disclosure relates to compounds for the use of treating neurodegenerative diseases and, in particular, to compounds targeting the Abelson non-tyrosine kinase (c-Abl) protein for such treatment. The neurological disorders and conditions include Parkinson's disease, Alzheimer's disease and the like. It also relates to pharmaceutical compositions and methods of treatment of such neurological disorders involving the c-Abl protein kinase.

Abelson non-tyrosine kinase compounds for the treatment of neurodegenerative diseases

Disclosed herein are compounds having antiviral activity, and, in particular, an inhibitory activity on the replication of Respiratory Syncytial Virus (RSV). Druggable target sites, including Px, in the RSV N protein are disclosed, as well as compounds targeting Px. The compounds can be used to treat patients with RSV infection.

Inhibitors of RSV replication and applications thereof

This disclosure relates to phosphoinositide 3-kinases (PI3Ks) inhibitors such as N-(5-(imidazo[1,2-a]pyridin-6-yl)pyridin-3-yl)sulfonamide derivatives and uses related thereto. In certain embodiments, the disclosure relates to methods of treating PI3K associated diseases or conditions comprising administering an effective amount of a compound disclosed herein to a subject in need thereof. In certain embodiments, the subject is at risk of, exhibiting symptoms of, suffering from, or diagnosed with cancer or a hematological malignancy.

Phosphotidylinositol 3-kinase inhibitors

Growing community of inventors

East Point, GA, United States of America

Zackery Will Dentmon